BIAF

bioAffinity Technologies, Inc. (BIAF) 10Y Growth Potential Analysis (2026)

Invetso Score: 2.7/10 — Weak · Last Updated: 2026-09-01

Monthly Update

No material changes this month.

Revenue Growth Drivers

Score: 2.8 (Weak)

BIAF lacks disclosed 5-year revenue CAGR and shows negative ROIC, limiting evidence of repeatable revenue compounding versus better-documented peers.

R&D intensity at 31.4% of revenue suggests heavy reinvestment, but absent proven monetization it has not translated into durable growth versus peers.

Low capex intensity indicates limited asset-heavy scaling needs, yet it also implies no clear operating leverage engine to accelerate long-term revenue expansion.

Negative interest coverage and weak profitability reduce internal funding capacity, constraining self-financed growth relative to peers with stronger cash generation.

Market Tailwinds

Score:

No peer-verified demand tailwind is evident in the provided metrics, so long-term growth depends more on execution than on a clearly expanding market.

The company’s revenue base is not supported by disclosed multi-year growth data, unlike peers with visible historical compounding and market adoption.

High R&D spend may indicate pipeline optionality, but without commercialization proof it does not establish a durable market-driven growth advantage.

Compared with peers that show positive returns and operating momentum, BIAF appears less positioned to convert external demand into sustained revenue growth.

Scalability Expansion

Score:

Very low capex-to-revenue suggests a potentially scalable model, but the absence of positive profitability weakens evidence that scale is already compounding revenue.

Negative ROIC implies incremental investment has not yet produced attractive returns, limiting confidence in reinvestment-led expansion versus stronger peers.

The company’s capital structure appears lightly levered, but weak earnings quality reduces the amount of internally generated capital available for scaling.

Without disclosed segment concentration or revenue CAGR, there is insufficient proof that the business can expand efficiently across multiple years.

Constraints Limitations

Score:

Negative ROIC is the clearest structural constraint because it signals that growth investment has not yet created value at scale versus peers.

Negative interest coverage indicates earnings are insufficient to comfortably service obligations, which can restrict reinvestment and slow expansion.

The lack of historical growth disclosure limits visibility into durability, making long-term scaling harder to underwrite than for peers with proven trajectories.

High R&D intensity without corresponding profitability suggests execution risk, because spending is elevated while monetization remains unproven.

Overall Score

Score:

BIAF shows some theoretical scalability from low capex and high R&D intensity, but negative ROIC and weak earnings conversion dominate the long-term growth outlook versus peers.

Score Driver: Negative Roic

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on bioAffinity Technologies, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →